Course Opens
01/15/2025
Credits
1
Credit Expires
01/15/2026
In the United States, diffuse large B-cell lymphoma (DLBCL) has an incidence rate of 5.5-7.2 per 100,000 individuals, and a death rate of 1.7 per 100,000. Despite its prevalence, integrating the necessary diagnostic and prognostic markers remains a challenge for most clinicians. Up to 40% of patients with DLBCL do not respond to first line (1L) treatments, necessitating a search for new targets beyond CD20. New therapies are being explored in the treatment of DLBCL with a focus on more targeted and personalized treatments. Despite an array of new options, there is currently no established optimal sequence of drugs or consensus on the best order of administration, highlighting the need for further education.
In this virtual CE Concepts Grand Rounds, expert faculty will discuss strategies to better integrate diagnostic and prognostic biomarkers for DLBCL, utilize an evidence-based approach for personalizing treatment for patients with R/R DLBCL, and identify and mitigate the impact of AEs associated with novel therapies used in the treatment of patients with R/R DLBCL.
At the conclusion of this activity, learners will be able to better:
This program is supported by independent educational grants from ADC Therapeutics America, Inc., and Pfizer Inc.
Academic and community-based hematologist/oncologists, nurses, nurse practitioners (NPs), and physician associates (PAs), and pharmacists specializing in oncology
In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Creative Educational Concepts, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.00 contact hours ( 0.1 CEUs) of continuing pharmacy credit ( JA0007101-0000-24-020-H01-P ).
This activity is designated for 1.00 contact hours.
This activity is designated for 1.00 contact hours.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:
OCN®
CBCN®
CPHON®
AOCNP*
BMTCN®
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.
Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 01/15/2026. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Faculty
Dr. Allan reports the following financial relationships:
Advisory Board: NeoGenomics Laboratories
Consultant: AbbVie Inc.; Adaptive Biotechnologies; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc. (DMSB Chair); and Pharmacyclics
Research Support: BeiGene; Celgene Corporation/Bristol Myers Squibb; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.
Speakers Bureau: AbbVie Inc. and BeiGene
Planner
Dr. Kurtin reports the following financial relationships:
Advisory Board and Consultant: Agios Pharmaceuticals, Inc. and GSK
The following individuals have no financial relationships to disclose:
Alaa Bawaneh, MD, PhD (Peer Reviewer)
Margaret Wright, BSN, RN (Peer Reviewer)
Evan Luberger (Planning Committee)
Sireesha Murala, MD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Post-tests, credit request forms, and activity evaluations must be completed online
(requires free account activation), and participants can print their certificate or statement of
credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.
Call us at 859-260-1717 • info@ceconcepts.com
GRV-079
Call us at 859-260-1717 • info@ceconcepts.com
